Understanding how kidney tumors use nutrients for growth

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the metabolism of kidney cancers, including renal cell and urothelial carcinomas, by using specially labeled nutrient tracers during surgical procedures. Participants will receive an infusion of 13C-labeled nutrients, and blood samples will be collected to monitor safety and nutrient utilization. Tissue samples will also be collected to analyze how cancer cells use these nutrients for growth. The findings aim to enhance understanding of cancer metabolism and support the development of targeted therapies and non-invasive imaging techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients must have radiographic evidence of known or probable kidney or urothelial cancer requiring surgical biopsy or excision.
* Age ≥ 18 years
* Subjects of all races and ethnic origins
* The willingness to sign and ability to understand a written informed consent.
* Patients participating in other clinical trials are eligible, and will be evaluated on a case by case basis by the Principal Investigator, Dr. Vitaly Margulis, MD.

Exclusion Criteria:

* Uncontrolled or poorly controlled diabetes for patients receiving a 13C infusion
* Pregnant or breastfeeding
* Not a surgical candidate

Where it's running

• University of Texas Southwestern Medical Center
  Dallas, Texas, United States Recruiting

Study contacts

• Principal investigator: Vitaly Margulis, MD — University of Texas Southwestern Medical Center
• Study coordinator: Vitaly Margulis, MD
• Email: vitaly.margulis@utsouthwestern.edu
• Phone: 214-648-0567

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing home and clinic administration of nivolumab for cancer treatment

  This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT06265285

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma

  This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07492628

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

• Nerve effects of enfortumab vedotin in people with urothelial cancer

  We will see how nerve testing and patient-reported symptoms change in adults with urothelial cancer who are starting enfortumab vedotin.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07390617

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.